Filtered By:
Management: National Institute for Health and Clinical Excelle
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 155 results found since Jan 2013.
Supporting the commissioning of anticoagulation therapy for adults
This resource supports commissioners to review how anticoagulation therapy is currently initiated, provided, monitored and reviewed in their local area with particular consideration to the introduction of the novel oral anticoagulants. NICE recommendations for rivaroxaban, dabigatran and apixaban for stroke prevention in people with atrial fibrillation and rivaroxaban for treatment of deep vein thrombosis provide people who have these conditions with more choices of medication. This will have an impact on the commissioning of anticoagulation services at a local level, with an anticipated reduction in vitamin K antagonist monitoring services.
Source: NHS Networks - May 23, 2013 Category: UK Health Authors: Maria Axford Source Type: news
Metformin may not reduce cardiovascular risk or all-cause mortality
Commentary on: Boussageon R, Supper I, Bejan-Angoulvant T, et al.. Reappraisal of metformin efficacy in the treatment of Type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9:268–82. Context The treatment of hyperglycaemia is considered as one of the tools for preventing cardiovascular disease in Type 1 and Type 2 diabetic (T2D) patients.1 2 Metformin is recommended as the first-line drug for T2D by most international guidelines (IDF.2005. http://www.idf.org, 2007. http://www.aace.com, http://www.diabetesjournals.org, http://www.nice.org.uk/CG66). The preference for metformin over other av...
Source: Evidence-Based Medicine - March 19, 2013 Category: Internal Medicine Authors: Monami, M. Tags: Geriatric medicine, Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Diet, Ischaemic heart disease, Diabetes Online articles Source Type: research
New stroke prevention treatment recommended by NICE
Atrial
fibrillation (AF) is the most common
cause of irregular heart beat. It can cause the heart rhythm to become
disorganised, and on occasion too fast, leading to the inefficient pumping of
blood around the body.
Source: NHS Networks - February 28, 2013 Category: UK Health Authors: Karen Topping Source Type: news
NICE costing statement for its guidance on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE
Area: News
NICE has published a costing statement to accompany its guidance on the use of apixaban for preventing stroke and systemic embolism in nonvalvular atrial fibrillation (TA 275).
The statement notes that "Apixaban provides an alternative treatment option at a comparable cost and therefore it is anticipated that there will not be a significant cost impact as a result of implementing this guidance."
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news
NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE
Area: Evidence > Guidelines
NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:
. prior stroke or transient ischaemic attack
. age 75 years or older
. hypertension
. diabetes mellitus
. symptomatic heart failure.
NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news
InFocus: Plans to Streamline Stroke Research in the Works
HONOLULU (MedPage Today) -- Wouldn't it be nice if a clinical trial took only months to initiate rather than years? The NIH thinks so too and has a plan to make that dream come true, deputy director Walter Koroshetz, MD, said in this exclusive InFocus interview.
Source: MedPage Today Cardiovascular - February 11, 2013 Category: Cardiology Source Type: news
Lucy Mangan: wanted – mother for Neanderthal baby
'Don't you long, occasionally, for something really, really interesting, something different, something overwhelmingly "other" to happen?'It's possible that the snow has driven me stir crazy. Although, as someone who, when under stress, still draws diagrams of the underground, Womble burrow-based home that she plans to build when she wins the lottery, I think that is highly unlikely. In any case, I have been seized by the idea of having another baby.Not just any old baby – I've already got one of those – but a Neanderthal baby. Earlier this week Professor George Church, a genetic researcher at Harva...
Source: Guardian Unlimited Science - January 26, 2013 Category: Science Authors: Lucy Mangan Tags: The Guardian Family Genetics Evolution Biology Parents and parenting Anthropology Features Life and style Neanderthal man Science Source Type: news
NICE Final Appraisal Determination on ELIQUIS®
Bristol-Myers Squibb and Pfizer Ltd. have announced that the National Institute for Health and Clinical Excellence (NICE) has issued a fast-tracked Final Appraisal Determination (FAD) recommending the oral anticoagulant Eliquis (apixaban) as an option for preventing stroke and systemic embolism, in patients with non-valvular atrial fibrillation (AF) with one or more risk factors.
Source: Pharmacy Europe - January 24, 2013 Category: Drugs & Pharmacology Source Type: news
NICE backs drug to reduce stroke risk for AF patients
The National Institute for Clinical Excellence is now recommending the use of apixaban for some patients with irregular heartbeats to help prevent them experiencing stroke or systemic embolism.
Source: Nursing Times Breaking News - January 23, 2013 Category: Nursing Source Type: news
NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE
Area: News
In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).
The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news
Pfizer anti-stroke drug apixaban now available on UK NHS
The UK's National Institute for Health and Clinical Excellence (NICE) has announced it is now recommending NHS doctors in England and Wales prescribe new drug apixaban for the prevention of stroke.
Source: Pharmaceutical Technology - January 23, 2013 Category: Pharmaceuticals Source Type: news
NICE guidance supports new blood pressure device that can detect atrial fibrillation
The guidance backs use of WatchBP Home A, which could reduce the incidence of atrial fibrillation-related stroke by improving early detection.
The guidance also recommends that WatchBP Home A should be considered for use in people with suspected hypertension (high blood pressure) or those being screened for hypertension in primary care.
Source: NHS Networks - January 21, 2013 Category: UK Health Authors: Maria Axford Source Type: news
Watchdog Backs AF Blood Pressure Device
Detection and treatment of dangerous atrial fibrillation is vital A new blood pressure measuring device that can also detect a dangerous heart condition has been backed by the health watchdog. New guidance from the National Institute for Clinical Excellence (NICE) supports the use of the 'WatchBP Home A' device by healthcare professionals in primary care to opportunistically detect atrial fibrillation (AF) during measurement of blood pressure. AF is one of the most common types of abnormal heart rhythm and a major cause of stroke if left untreated...
Source: Health News from Medical News Today - January 18, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news
Doctors urged to use a new blood pressure test to predict the risk of patients having a stroke
The National Institute for Health and Clinical Excellence (Nice) said if doctors suspect a patient has high blood pressure, they should use the WatchBP Home A device which could ‘opportunistically’ detect atrial fibrillation.
Source: the Mail online | Health - January 16, 2013 Category: Consumer Health News Source Type: news
NHS Evidence expert commentary: Benefits of drug therapy are unclear for mild hypertension
Source: NHS Evidence
Area: News
The January edition of 'Eyes on Evidence', the free monthly e-bulletin from NHS Evidence covering major new published evidence as it emerges with an explanation about what it means for current practice, includes an expert commentary on new data from a Cochrane review that aimed to quantify the effects of antihypertensive drug therapy versus no treatment on mortality and morbidity in adults with mild hypertension and no evidence of cardiovascular disease. It included four RCTs with 8912 participants. The review concluded that, compared with placebo, antihypertensive treatment does not reduce...
Source: NeLM - Cardiovascular Medicine - January 10, 2013 Category: Cardiology Source Type: news
